M.W. Roomi, V. Ivanov, A. Niedzwiecki, M. Rath
Third International Kidney Cancer Symposium, Chicago, Illinois, November 12-14 2004.
The Third International Kidney Cancer Symposium proceedings, Abstract #39, pg 39.
Renal adenocarcinoma, the 17th most frequent cancer worldwide, is associated with good prognosis if treated when still localized to the kidney; however, once metastasized, prognosis is poor. We investigated the effect of a unique nutrient formulation (NM) of lysine, proline, arginine, ascorbic acid, and epigallocatechin gallate on its effect in vitro on modulation of metastatic parameters in human renal adenocarcinoma cell line 786-0. NM significantly inhibited MMP expression and Matrigel invasion in a dose-dependent fashion, with total inhibition of MMP-2 at 500 µg/ml, MMP-9 at 100 µg/ml and invasion at 1000 µg/ml. These results indicate NM has great potential in therapeutic use for treatment of renal carcinoma.